Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Arena Oncology Associates PC
mi
from
Lake Success, NY
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Arena Oncology Associates PC
mi
from
Lake Success, NY
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Hanover Medical Specialists
mi
from
Wilmington, NC
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Hanover Medical Specialists
mi
from
Wilmington, NC
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Gabrail Cancer Center
mi
from
Canton, OH
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Arlington Cancer Center
mi
from
Arlington, TX
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Arlington Cancer Center
mi
from
Arlington, TX
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Baylor College of Medicine
mi
from
Houston, TX
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
South Texas Onocology Hemotology, PA
mi
from
San Antonio, TX
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
South Texas Onocology Hemotology, PA
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Providence Western Washington Oncology
mi
from
Lacey, WA
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Providence Western Washington Oncology
mi
from
Lacey, WA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Medical College of Wisconsin - Clinical Cancer Center
mi
from
Milwaukee, WI
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Medical College of Wisconsin - Clinical Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Centre Hospitalier Jolimont-Lobbes
mi
from
Haine Saint Paul,
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Centre Hospitalier Jolimont-Lobbes
mi
from
Haine Saint Paul,
Click here to add this to my saved trials
A Phase I/Expansion Study of Dasatinib
A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer
Status: Enrolling
Updated:  9/4/2015
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
A Phase I/Expansion Study of Dasatinib
A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer
Status: Enrolling
Updated: 9/4/2015
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase I/Expansion Study of Dasatinib
A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer
Status: Enrolling
Updated:  9/4/2015
Duke Univ Med Ctr
mi
from
Durham, NC
A Phase I/Expansion Study of Dasatinib
A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer
Status: Enrolling
Updated: 9/4/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase I/Expansion Study of Dasatinib
A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer
Status: Enrolling
Updated:  9/4/2015
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
A Phase I/Expansion Study of Dasatinib
A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer
Status: Enrolling
Updated: 9/4/2015
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Jonesboro, AR
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Corona, CA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Corona, CA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Miami, FL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Wichita, KA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Mt Sterling, KY
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Mt Sterling, KY
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Bethesda, MD
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Detroit, MI
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Bismarck, ND
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Bismarck, ND
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Eugene, OR
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Germantown, TN
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Germantown, TN
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Newport News, VA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Newport News, VA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Hot Springs, AR
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Fountain Valley, CA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Riverside, CA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Evergreen Park, IL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Park Ridge, IL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Skokie, IL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Tucuman,
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Tucuman,
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Anaheim/Orange County
mi
from
Anaheim, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Anaheim/Orange County
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Baldwin Park
mi
from
Baldwin Park, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Baldwin Park
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Bellflower
mi
from
Bellflower, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Bellflower
mi
from
Bellflower, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Fontana
mi
from
Fontana, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Fontana
mi
from
Fontana, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Harbor City
mi
from
Harbor City, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Harbor City
mi
from
Harbor City, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Irvine
mi
from
Irvine, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Foundation Hospital - West Los Angeles
mi
from
Los Angeles, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Foundation Hospital - West Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Ontario Vineyard Medical Offices and Ambulatory SurgiCenter
mi
from
Ontario, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Ontario Vineyard Medical Offices and Ambulatory SurgiCenter
mi
from
Ontario, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Redwood City
mi
from
Redwood City, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Redwood City
mi
from
Redwood City, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Richmond
mi
from
Richmond, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Richmond
mi
from
Richmond, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Riverside
mi
from
Riverside, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
South Sacramento Kaiser-Permanente Medical Center
mi
from
Sacramento, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
South Sacramento Kaiser-Permanente Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials